WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer, a global leader in radiology, has initiated the Phase III clinical development program called QUANTI, aiming to evaluate the safety and efficacy of gadoquatrane ...
CORVALLIS, Ore. (KTVZ) -– Scientists at Oregon State University have filed a patent on a design for a new magnetic resonance imaging contrast agent with the potential to outperform current agents ...
BERLIN--(BUSINESS WIRE)--Bayer, a global leader in radiology, today announced positive topline results of the pivotal Phase III QUANTI studies evaluating the efficacy and safety of gadoquatrane, an ...
Scientists at Oregon State University have filed a patent on a design for a new magnetic resonance imaging contrast agent with the potential to outperform current agents while being less toxic to ...
Bayer revealed first results of the pediatric study from the pivotal clinical development program QUANTI for its low-dose MRI contrast agent QUANTI Pediatric evaluated the pharmacokinetics and safety ...
Scientists at the University of Birmingham have developed a new class of MRI contrast agents: improving their stability to create a significant advancement in medical imaging technology. Metallo ...
Half-dose gadopiclenol provides equal or better breast MRI contrast than full-dose gadobutrol. Find out how it could reduce ...
Magnetic resonance imaging (MRI) has become an indispensable diagnostic modality in clinical medicine. Cluster-based magnetic resonance imaging contrast agents (MRICAs) demonstrate significant ...
Medical imaging often facilitates the successful diagnosis and management of cancerous growths. In particular, magnetic resonance imaging (MRI) is extensively used, especially with contrast agents, ...
Researchers at Rice University and Oak Ridge National Laboratory have unveiled a physics-based model of magnetic resonance relaxation that bridges molecular-scale dynamics with macroscopic magnetic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results